BioAge Labs, Inc. AI Stock Analysis
Want to see BIOA full AI Analyst Report?
BioAge Labs, Inc. (BIOA) AI Stock Analysis
BioAge Labs, Inc.
(NASDAQ:BIOA)
BIOA scores low primarily due to weak financial performance driven by substantial losses and persistent negative free cash flow, which implies ongoing financing needs. Technicals are also unfavorable with the price below key moving averages and negative MACD. These are partially offset by a strong, low-leverage balance sheet and a positive Phase 2 trial initiation that improves the longer-term outlook.
BioAge Labs, Inc. (BIOA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $208.96M
- Dividend Yield
- ―
- Average Volume (3M)
- 733.47K
- Price to Earnings (P/E)
- -2.2
- Beta (1Y)
- 1.85
- Revenue Growth
- 45.33%
- EPS Growth
- -20.81%
- Country
- US
- Employees
- 61
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
BioAge Labs, Inc. Business Overview & Revenue Model
Company Description
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights...
BioAge Labs, Inc. Financial Statement Overview
Summary
Financial performance is pressured by large ongoing losses and heavy cash burn (TTM net loss ~$107.8M; TTM operating cash flow about -$102.5M and free cash flow about -$103.0M). The balance sheet is a relative strength with very low leverage (debt-to-equity ~0.01) and substantial equity (~$346.4M), but negative returns (TTM ROE ~-29%) indicate continued erosion risk if burn persists.
Income Statement
24NegativeBalance Sheet
72PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.60M | 8.99M | 0 | 0 | 0 |
| Gross Profit | 8.54M | 8.99M | 0 | 0 | 0 |
| EBITDA | -107.38M | -79.69M | -68.58M | -55.90M | -39.35M |
| Net Income | -107.80M | -80.61M | -71.11M | -63.85M | -39.72M |
Balance Sheet | |||||
| Total Assets | 367.65M | 294.89M | 358.23M | 25.92M | 28.43M |
| Cash, Cash Equivalents and Short-Term Investments | 283.64M | 281.10M | 354.35M | 21.64M | 27.64M |
| Total Debt | 2.73M | 5.56M | 8.70M | 53.25M | 2.47M |
| Total Liabilities | 21.20M | 22.84M | 35.11M | 199.32M | 140.99M |
| Stockholders Equity | 346.45M | 272.05M | 323.13M | -173.40M | -112.56M |
Cash Flow | |||||
| Free Cash Flow | -103.00M | -82.35M | -51.89M | -37.53M | -36.28M |
| Operating Cash Flow | -102.52M | -81.63M | -51.52M | -37.36M | -36.18M |
| Investing Cash Flow | -218.15M | -95.22M | -366.00K | -266.00K | -103.00K |
| Financing Cash Flow | 157.78M | 11.47M | 381.20M | 34.94M | 2.50M |
BioAge Labs, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOA, the sentiment is Negative. The current price of 5.22 is below the 20-day moving average (MA) of 5.60, below the 50-day MA of 6.60, and below the 200-day MA of 15.12, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 41.92 is Neutral, neither overbought nor oversold. The STOCH value of 46.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOA.
BioAge Labs, Inc. Risk Analysis
BioAge Labs, Inc. disclosed 66 risk factors in its most recent earnings report. BioAge Labs, Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksBioAge Labs, Inc. Peers Comparison
Overall Rating
IRWD72Outperform
DERM50Neutral
LFCR50Neutral
BIOA45Neutral
IXHL43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | $799.61M | 5.33 | -93.40% | ― | 18.09% | 403.76% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 50Neutral | $122.21M | -23.29 | -16.07% | ― | 17.03% | 49.40% | |
| 50Neutral | $243.36M | -3.40 | 381.59% | ― | ― | ― | |
| 45Neutral | $255.07M | -2.18 | -31.42% | ― | 45.33% | -20.81% | |
| 43Neutral | $24.72M | -2.94 | -12.40% | ― | -100.00% | 96.25% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BIOA | BioAge Labs, Inc. | 5.22 | -3.03 | -36.73% | |
| IRWD | Ironwood Pharmaceuticals | 4.85 | 1.74 | 55.95% | |
| LFCR | Lifecore Biomedical, Inc. | 6.42 | -1.18 | -15.59% | |
| SXTC | China Sxt Pharmaceuticals | 2.99 | -1919997.01 | -100.00% | |
| DERM | Journey Medical Corporation | 3.70 | -4.25 | -53.46% | |
| IXHL | Incannex Healthcare Limited Sponsored ADR | 1.93 | -8.56 | -81.61% |
BioAge Labs, Inc. Corporate Events
BioAge Labs initiates Phase 2 trial for BGE-102
PositiveBioAge Labs announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial testing once-daily oral NLRP3 inhibitor BGE-102 in adults with diabetic macular edema. The roughly 180-subject study will compare BGE...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
